China Health Industries Holdings Inc
OTC:CHHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Health Industries Holdings Inc
Research & Development
China Health Industries Holdings Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Health Industries Holdings Inc
OTC:CHHE
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Research & Development
-¥209.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Research & Development
-¥82.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
S
|
Shanghai Chicmax Cosmetic Co Ltd
HKEX:2145
|
Research & Development
-¥179.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Research & Development
-¥88.8m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
China Health Industries Holdings Inc
Glance View
China Health Industries Holdings, Inc. engages in the production, marketing, and distribution of medicines, health products, health devices, and cosmetics. The company is headquartered in Harbin, Heilongjiang and currently employs 49 full-time employees. The company went IPO on 2004-12-01. The firm's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The firm has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The firm's products are sold through sales agents.
